The Latest about Neuros

Releases

• Twelve-Month Results from Landmark QUEST Study Published in Neuromodulation
• Neuros Medical Receives FDA Approval for the Altius® Direct Electrical Nerve Stimulation System
• Neuros Medical Strengthens Senior Leadership Team in Preparation for Commercialization of the Altius® System
• Landmark Study of a Revolutionary Device for the Treatment of Post Amputation Pain Accepted for Publication in the Journal of Pain Research
• Neuros Medical, Inc. Names David Veino as President and CEO and Expands Board of Directors
• Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints
• Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain
• Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System
• Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
• Neuros Medical Announces Key Milestones in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain
• Neuros Medical Appoints Tom Wilder as President and CEO
• Neuros Medical Announces Closing of $20 Million Venture Financing